MedTrace Logo

Adjunct Minocyline in Treatment-resistant Depression

NCT02456948 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 168

Last updated 2020-10-19

No results posted yet for this study

Summary

This study examines the antidepressant efficacy of minocycline as an adjunct to an antidepressant standard treatment (AD-ST), for patients with unipolar major depressive disorder (MDD).

Conditions

Interventions

DRUG

Minocycline

6 weeks 200mg/day Minocycline add-on

DRUG

Placebo

6 weeks Placebo add-on

Sponsors & Collaborators

  • Charite University, Berlin, Germany

    lead OTHER

Principal Investigators

  • Isabella Heuser, MD, PhD · Chair: Department of Psychiatry Charité - Campus Benjamn

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2020-08-07
Completion
2020-08-07

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02456948 on ClinicalTrials.gov